Molnupiravir

 化学構造式
2349386-89-4
CAS番号.
2349386-89-4
化学名:
别名:
英語名:
Molnupiravir
英語别名:
Molnupiravir;EIDD-2801;((2R,3S,4R,5R)-3,4-dihydroxy-5-((E)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl isobutyrate;((2R,3S,4R,5R)-3,4-dihydroxy-5-(4-(hydroxyamino)-2-oxopyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl isobutyrate;Tube994;Molnupiravir(MK-4482);Molnupiravir(EIDD-2801);IDD-2801;Mopiravir;EIDO-2801
CBNumber:
CB85851964
化学式:
C13H19N3O7
分子量:
329.31
MOL File:
2349386-89-4.mol

Molnupiravir 物理性質

融点 :
156 - 159°C
貯蔵温度 :
-20°C, Inert atmosphere
溶解性:
DMSO(微量)、メタノール(微量)
外見 :
個体
色:
ホワイトからオフホワイト
InChI:
InChI=1/C13H19N3O7/c1-6(2)12(19)22-5-7-9(17)10(18)11(23-7)16-4-3-8(15-21)14-13(16)20/h3-4,6-7,9-11,17-18,21H,5H2,1-2H3,(H,14,15,20)/t7-,9-,10-,11-/s3
InChIKey:
HTNPEHXGEKVIHG-JFPRWSRANA-N
SMILES:
O[C@@H]1[C@@H]([C@@H](COC(=O)C(C)C)O[C@H]1N1C=C/C(=N/O)/NC1=O)O |&1:1,2,3,12,r|
安全性情報
  • リスクと安全性に関する声明
  • 危険有害性情報のコード(GHS)
絵表示(GHS) GHS hazard pictograms
注意喚起語
危険有害性情報
コード 危険有害性情報 危険有害性クラス 区分 注意喚起語 シンボル P コード
H372 長期にわたる、または反復暴露により臓器の障 害 特定標的臓器有害性、単回暴露 1 危険 GHS hazard pictograms P260, P264, P270, P314, P501
注意書き
P260 粉じん/煙/ガス/ミスト/蒸気/スプレーを吸入しないこ と。
P264 取扱い後は皮膚をよく洗うこと。
P264 取扱い後は手や顔をよく洗うこと。
P270 この製品を使用する時に、飲食または喫煙をしないこ と。
P314 気分が悪い時は、医師の診断/手当てを受けること。
P501 内容物/容器を...に廃棄すること。

Molnupiravir 価格 もっと(2)

メーカー 製品番号 製品説明 CAS番号 包装 価格 更新時間 購入
Sigma-Aldrich Japan SML2873 ≥98% (HPLC)
EIDD-2801 ≥98% (HPLC)
2349386-89-4 5MG ¥14500 2024-03-01 購入
Sigma-Aldrich Japan SML2873 ≥98% (HPLC)
EIDD-2801 ≥98% (HPLC)
2349386-89-4 25MG ¥58400 2024-03-01 購入

Molnupiravir 化学特性,用途語,生産方法

説明

EIDD-2801 is an orally bioavailable prodrug of the antiviral nucleoside derivative N4- hydroxycytidine (NHC, EIDD-1931). It is a nucleotide analog inhibitor of RNA-dependent RNA polymerases (RdRps). The compound interferes with the action of viral RNA polymerase. It exerts its antiviral action through introduction of copying errors during viral RNA replication. The active drug incorporates into the genome of RNA viruses, leading to an accumulation of mutations known as viral error catastrophe. The broadspectrum antiviral agent EIDD-2801 inhibits viral RNA replication in various unrelated RNA viruses including influenza, Ebola, Venezuelan equine encephalitis virus (VEEV) and coronaviruses, including SARS-CoV, MERS-CoV and SARS-CoV-2. EIDD-2801 has the potential for COVID-19, seasonal and pandemic influenza treatment.

来歴

Molnupiravir (EIDD-2801/MK-4482) is an investigational, orally bioavailable form of a potent ribonucleoside analog that inhibits the replication of multiple RNA viruses including SARS-CoV-2, the causative agent of COVID-19. Molnupiravir has been shown to be active in several models of SARS-CoV-2, including for prophylaxis, treatment and prevention of transmission, as well as SARS-CoV-1 and MERS. EIDD-2801 was invented at Drug Innovations at Emory (DRIVE), LLC, a not-for-prot biotechnology company wholly owned by Emory University, and with partial funding support from the U.S. government. Since licensed by Ridgeback, all funds used for the development of EIDD-2801 by Ridgeback have been provided by Wayne and Wendy Holman and Merck.

使用

EIDD 2801 is an orally bioavailable broad-spectrum antiviral that inhibits SARS-CoV-2 and other multiple endemic, epidemic and bat coronavirus and has the potential for seasonal and pandemic influenza treatment. An isopropylester prodrug of the ribonucleoside analog of EIDD-1931 that exhibits anti-influenza virus and coronaviruses activities.

定義

Molnupiravir is a nucleoside analogue that is N(4)-hydroxycytidine in which the 5'-hydroxy group is replaced by a (2-methylpropanoyl)oxy group. It is the prodrug of the active antiviral ribonucleoside analog N(4)-hydroxycytidine (EIDD-1931), has activity against a number of RNA viruses including SARS-CoV-2, MERS-CoV, and seasonal and pandemic influenza viruses. It is currently in phase III trials for the treatment of patients with COVID-19. It has a role as a prodrug, an anticoronaviral agent and an antiviral drug. It is a nucleoside analogue, an isopropyl ester and a ketoxime. It derives from a N(4)-hydroxycytidine.
www.ebi.ac.uk

生物活性

EIDD-2801 is an orally active, 5′-isopropylester prodrug form of the antiviral ribonucleoside analog N4-hydroxycytidine (NHC, EIDD-1931) with known anti-viral activity against SARS-CoV, SARS-CoV-2, RSV, influenza A & B (IAV & IBV), HCV, pestivirus, bovine viral diarrhoea virus (BVDV), Ebola (EBOV), Chikungunya (CHIKV), venezuelan equine encephalitis (VEEV). EIDD-2801 is efficiently hydrolyzed to NHC in vivo, being more orally bioavailable than NHC in nonhuman primates and ferrets, while maintaining similar oral bioavailability as NHC in mice. EIDD-2801 displays in vivo efficacy against pandemic and seasonal IAV strains in ferrets (lowest ED = 2.3 and 7 mg/kg b.i.d. p.o., respectively).

規制状況(Regulatory Status)

Molnupiravir (as EIDD-2801) was developed at Drug Innovation Ventures at Emory (DRIVE), a not-forprofit biotechnology company owned by Emory University, Atlanta. It was then licensed by Ridgeback Biotherapeutics, and is now developed further in cooperation with Merck & Co. (in Europe: Merck Sharp & Dohme/ MSD).
Molnupiravir is not approved by the European Medicines Agency (EMA) or the American Food and Drug Administration (FDA).

参考文献

[1] Toots M, Yoon J-J, Cox RM et al. Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Science Translational Medicine 2019;11(515). Epub 23 Oct 2019.
[2] Toots M, Yoon J-J, Hart M et al. . Quantitative Efficacy Paradigms of the Influenza Clinical Drug Candidate EIDD-2801 in the Ferret Model. Transl Res 2020. Epub 2019 Dec 25.
[3] Halford B. An emerging antiviral takes aim at COVID-19. American Chemical Society; 2020 [14.12.2020]; Available from: https://cen.acs.org/pharmaceuticals/drug-development/emergingantiviral-takes-aim-COVID-19/98/web/2020/05.
[4] Ridgeback Biotherapeutics. OVERVIEW OF EIDD-2801 (MK-4482). [Presentation]. provided via email 2020.

Molnupiravir 上流と下流の製品情報

原材料

準備製品


Molnupiravir 生産企業

Global( 287)Suppliers
名前 電話番号 電子メール 国籍 製品カタログ 優位度
weifang runzhong fine chemical co., ltd
536-7868377 +8618653686003
sq@runzhongchem.com China 187 58
Wuhan Biocar Pharmacy Co., Ltd.
+86-13669031409 +8613669031409
jason@biocar.cn China 742 58
Jinan Jianfeng Chemical Co., Ltd
+8615562555968
info@pharmachemm.com China 246 58
HangZhou RunYan Pharma Technology Co.,LTD.
+86-88660901 +86-18112526015
sales@runyanpharma.com China 326 58
Hebei Yanxi Chemical Co., Ltd.
+8617531190177
peter@yan-xi.com China 5988 58
Anhui Ruihan Technology Co., Ltd
+8617756083858
daisy@anhuiruihan.com China 994 58
ATK CHEMICAL COMPANY LIMITED
+undefined-21-51877795
ivan@atkchemical.com China 32480 60
Shenzhen Nexconn Pharmatechs Ltd
+86-755-89396905 +86-15013857715
admin@nexconn.com China 7836 58
Jinan Carbotang Biotech Co.,Ltd.
+8615866703830
figo.gao@foxmail.com China 8136 58
Shaanxi Dideu Medichem Co. Ltd
+86-29-87569265 +86-18612256290
1056@dideu.com China 3959 58

2349386-89-4()キーワード:


  • 2349386-89-4
  • EIDD-2801(EIDD 2801)
  • Uridine, 4-oxime, 5'-(2-methylpropanoate)
  • β-D-N4 hydroxycytidine-5'-isopropyl ester
  • MolnupiravirEIDD-2801(API)
  • UNII-YA84KI1VEW
  • EIDD-2801(Molnupiravir)
  • ((2R,3S,4R,5R)-3,4-dihydroxy-5-(4-(hydroxyamino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl isobutyrate
  • EIDO-2801
  • Molnupiravir-001
  • Molnupiravir (EIDD-2801, MK-4482)
  • Mopiravir
  • MK-4482/EIDD-2801
  • Molnupiravir-001-XA
  • ((2R,3S,4R,5R)-3,4-dihydroxy-5-((E)-4-(hydroxyimino)-2-oxo-3,4-dihydropyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl isobutyrate
  • EIDD-2801
  • Tube994
  • Molnupiravir(MK-4482)
  • Molnupiravir(EIDD-2801)
  • ((2R,3S,4R,5R)-3,4-dihydroxy-5-(4-(hydroxyamino)-2-oxopyrimidin-1(2H)-yl)tetrahydrofuran-2-yl)methyl isobutyrate
  • Horse, wei
  • 13C,15N2]-EIDD-2801
  • Molnupiravir
  • IDD-2801
  • Molunapiravir, API
  • Molnupiravir API
  • Molnupiravir EP Impurity-C
Copyright 2017 © ChemicalBook. All rights reserved